Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management

被引:94
|
作者
Pandey, Sanjay [1 ]
Srivanitchapoom, Prachaya [2 ]
机构
[1] Govind Ballabh Pant Postgrad Inst Med Educ & Res, Dept Neurol, Acad Block,Room 507, New Delhi 110002, India
[2] Mahidol Univ, Fac Med, Div Neurol, Dept Med,Siriraj Hosp, Salaya, Nakhon Pathom, Thailand
关键词
Dopamine; dyskinesia; levodopa; Parkinson's disease; NONHUMAN PRIMATE MODEL; PARKINSONS-DISEASE; L-DOPA; MOTOR FLUCTUATIONS; DOUBLE-BLIND; ANTAGONIST ISTRADEFYLLINE; EFFICACY; AMANTADINE; SYMPTOMS; COMPLICATIONS;
D O I
10.4103/aian.AIAN_239_17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients treated with levodopa. This side effect is usually encountered after long duration of treatment, but occasionally, this may be seen even after few days or months of treatment. LID is broadly classified as peak-dose dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control. Treatment of LID requires careful history taking and clinical examination to find the type of dyskinesia as different approach is required for different types. Changes in dopaminergic medication including continuous dopaminergic stimulation are very helpful in the management of peak-dose dyskinesia. Different types of surgical approaches including unilateral pallidotomy and deep brain stimulation have given very good result in patients, who cannot be managed by medications alone. The surgical management of LID is dealt with in detail in another review in this series.
引用
收藏
页码:190 / 198
页数:9
相关论文
共 50 条
  • [1] Clinical Aspects and Management of Levodopa-Induced Dyskinesia
    Tambasco, Nicola
    Simoni, Simone
    Marsili, Erica
    Sacchini, Elisa
    Murasecco, Donatella
    Cardaioli, Gabriela
    Rossi, Aroldo
    Calabresi, Paolo
    PARKINSONS DISEASE, 2012, 2012
  • [2] Management of levodopa-induced dyskinesia
    Rascol, O
    Ferreira, JJ
    Payoux, R
    Brefel-Courbon, C
    Montastruc, JL
    REVUE NEUROLOGIQUE, 2002, 158 : S117 - S124
  • [3] Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
    Tran, Tai N.
    Vo, Trang N. N.
    Frei, Karen
    Truong, Daniel D.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (08) : 1109 - 1117
  • [4] Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
    Tai N. Tran
    Trang N. N. Vo
    Karen Frei
    Daniel D. Truong
    Journal of Neural Transmission, 2018, 125 : 1109 - 1117
  • [5] Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
    Erwan Bezard
    Jonathan M. Brotchie
    Christian E. Gross
    Nature Reviews Neuroscience, 2001, 2 : 577 - 588
  • [6] LEVODOPA-INDUCED DYSKINESIA - CLINICAL OBSERVATIONS
    FRIEDMAN, A
    JOURNAL OF NEUROLOGY, 1985, 232 (01) : 29 - 31
  • [7] Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
    Bezard, E
    Brotchie, JM
    Gross, CE
    NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) : 577 - 588
  • [8] Clinical pharmacology of levodopa-induced dyskinesia
    Nutt, JG
    ANNALS OF NEUROLOGY, 2000, 47 (04) : S160 - S166
  • [9] Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia
    Barroso-Chinea, Pedro
    Bezard, Erwan
    FRONTIERS IN NEUROANATOMY, 2010, 4
  • [10] Reversal of Levodopa-Induced Dyskinesia
    Alias, Mathew
    Hassan, Mohamed
    ANNALS OF NEUROLOGY, 2012, 72 : S91 - S91